AmStem optimistic about study results
This article was originally published in The Rose Sheet
Executive Summary
San Francisco-based firm - whose Korean facility houses one of the largest banks in the world for umbilical-cord-derived stem cells - announces positive early results from a preliminary consumer study of its SteMixx face cream. More than 64% of responding participants from 21-woman study have made positive comments about the product, says AmStem, which will release full results at the end of the month. Based on initial feedback, "AmStem has engaged a labeling consultant ... to make [SteMixx] available for retail consumer use as soon as possible in the U.S." Firm also says it has finalized its submission to an institutional review board to begin first clinical trial of SteMixx in the U.S. (1"The Rose Sheet" June 21, 2010, Marketing In Brief). SteMixx employs Human Stem Cell Conditioned Media, created during culture of umbilical cord stem cells, to stimulate user's own inherent skin cells and promote skin rejuvenation